Ключові слова
Урсодезоксихолева кислота, TGR5, лікування захворювань печінки, метаболічний синдром
Як цитувати
Zhuravlyova, L., & Shekhovtsova, Y. (2018). ПАТОГЕНЕТИЧНЕ ОБҐРУНТУВАННЯ ВИКОРИСТАННЯ УРСОДЕЗОКСИХОЛЕВОЇ КИСЛОТИ В КЛІНІЧНІЙ ПРАКТИЦІ. Практикуючий лікар, (2), 45-51. вилучено із https://plr.com.ua/index.php/journal/article/view/17
Анотація
В оглядовій статті наведено сучасні уявлення про застосування урсодезоксихолевої кислоти в клінічній практиці. TGR5 та G-протеїнові рецептори мембрани, які активуються жовчними кислотами, дуже поширені в тканинах організму як тварин, так і людей. Переважно тканинна локалізація TGR5 зумовлює біологічні ефекти активації цих рецепторів. Представлений огляд сфокусований на ролі TGR5 як нового фармакологічного напрямку лікування хворих на метаболічний синдром, цукровий діабет, ожиріння, атеросклероз, захворювання печінки та онкологічні процеси.
Посилання
1. Звенигородская Л.А., Лазебник Л.Б., Черкашова Е.А., Ефремов Л.И. Статиновый гепатит // Трудный пациент. — 2009. — Vol. (4-5). — P. 44-9.
2. Звенигородская Л.А., Мельникова Н.В. Гиполипидемическая терапия у больных с неалкогольной жировой болезнью печени: место гепатопротекторов // Гастроэнтерология. Приложение к журналу Consilium Medicum. — 2009. — № 1. — С. 32-6.
3. Abedin M.Z., Narins S.C., Park E.H. et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long–term study in prairie dogs // Dig. Dis. Sci. — 2002. — Vol. 47 (10). — Р. 2192-210.
4. Alemi F., Kwon E., Poole D.P. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia // Journal of Clinical Investigation. — 2013. — Vol. 123. — Р. 1513-30.
5. Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview // Heart. — 2004. — Vol. 90. — Р. 464-70.
6. Bernstein C., Holubec H., Bhattacharyya A.K. et al. Carcinogenicity of deoxycholate, a secondary bile acid // Archives of Toxicology. — 2011. — Vol. 85. — Р. 863-71.
7. Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hyperchole-sterolemia treatment: a prospective clinical trial (in Spanish) // Rev. Clin. Esp. — 2004. — Vol. 204 (12). — Р. 632-5.
8. Calmus Y., Guechot J., Podevin P. et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes // Hepatology. — 1992. — Vol. 16. — Р. 719-23.
9. Cao W., Tian W., Hong J. et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma // American Journal of Physiology — Gastrointestinal and Liver Physiology. — 2013. — Vol. 304. — Р. G322-G327.
10. Chen W. — D., Yu D., Forman B.M. et al. The deficiency of G-protein-coupled bile acid receptor gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis // Hepatology. — 2013. — Vol. 57 (2). — Р. 656-66.
11. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial // Circulation. — 2003. — Vol. 107. — Р. 3133-40.
12. Cipriani S., Mencarelli A., Chini M.G. et al. The bile acid receptor GPBAR‑1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis // PLoS ONE. — 2011. — Vol. 6. — Р. e25637.
13. Duboc H., Aelion H., Rainteau D. et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor? // Hepatology. — 2012. — Vol. 56. — Р. 24-6.
14. Evans K.A., Budzik B.W., Ross S.A. et al. Discovery of 3-aryl‑4-isoxazolecarboxamides as TGR5 receptor agonists // Journal of Medicinal Chemistry. — 2009. — Vol. 52. — Р. 7962-5.
15. Fiorucci S., Mencarelli A., Palladino G., Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders // Trends Pharmacol. Sci. — 2009. — Vol. 30. — Р. 570-80.
16. He G., Yu G. — Y., Temkin V. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stressdriven STAT3 activation // Cancer Cells. — 2010. — Vol. 17. — Р. 286-97.
17. Hong J., Behar J., Wands J. et al. Role of a novel bile acid receptor TGR5 in the development of osophageal adenocarcinoma // Gut. — 2010. — Vol. 59. — Р. 170-80.
18. Hov J.R., Keitel V., Laerdahl J.K. et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis // PLoS ONE. — 2010. — Vol. 5. — Р. e12403.
19. Ichikawa R., Takayama T., Yoneno K. et al. Bile acids induce monocyte differentiation toward interleukin‑12 hypo-producing dendritic cells via a TGR5-dependent pathway // Immunology. — 2012. — Vol. 136. — Р. 153-62.
20. Kawamata Y., Fujii R., Hosoya M. et al. A G protein-coupled receptor responsive to bile acids// Journal of Biological Chemistry. — 2003. — Vol. 278. — Р. 9435-40.
21. Keitel V., Donner M., Winandy S. et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells // Biochemical and Biophysical Research Communications. — 2008. — Vol. 372. — Р. 78-84.
22. Keitel V., Görg B., Bidmon H.J. et al. The bile acid receptor TGR5 (Gpbar‑1) acts as a neurosteroid receptor in brain // Glia. — 2010. — Vol. 58. — Р. 1794-805.
23. Keitel V., Reinehr R., Gatsios P. et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells // Hepatology. — 2007. — Vol. 45. — Р. 695-704.
24. Kida T., Tsubosaka Y., Hori M. et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells // Arteriosclerosis, Thrombosis, and Vascular Biology. — 2013. — Vol. 33. — Р. 1663-9.
25. Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) // Circulation. — 2004. — Vol. 109. — Р. 1594-602.
26. Maruyama T., Miyamoto Y., Nakamura T. et al. Identification of membrane-type receptor for bile acids (M-BAR) // Biochemical and Biophysical Research Communications. — 2002. — Vol. 298. — Р. 714-9.
27. Maruyama T., Tanaka K., Suzuki J. et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice // Journal of Endocrinology. — 2006. — Vol. 191. — Р. 197-205.
28. Marzioni M., Ueno Y., Glaser S. et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver // Liver International. — 2007. — Vol. 27. — Р. 558-68.
29. Müssig K., Staiger H., Machicao F. et al. Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus // Metabolism — Clinical and Experimental. — 2009. — Vol. 58. — Vol. 1809-11.
30. Pols T.W.H., Nomura M., Harach T. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading // Cell Metabolism. — 2011. — Vol. 14. — Р. 747-57.
31. Pols T.W.H., Noriega L.G., Nomura M. et al. The bile acid membrane receptor TGR5: a valuable metabolic target // Digestive Diseases. — 2011. — Vol. 29. — Р. 37-44.
32. Porez G., Prawitt J., Gross B., Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease // Journal of Lipid Research. — 2012. — Vol. 53. — Р. 1723-37.
33. Sandek A., Bauditz J., Swidsinski A. et al. Altered intestinal function in patients with chronic heart failure // J. Am. Coll. Cardiol. — 2007. — Vol. 50. — Р. 1561-69.
34. Sato H., Genet C., Strehle A. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea // Biochemical and Biophysical Research Communications. — 2007. — Vol. 362. — Р. 793-8.
35. von Haehling S., Schefold J.C., Jankowska E.A., Springer J., Vazir A., Kalra P.R., Sandek A., Fauler G., Stojakovic T., Trauner M., Ponikowski P., Volk H. — D., Doehner W., Coats A.J.S., Poole-Wilson P.A., Anker S.D. Ursodeoxycholic Acid in Patients With Chronic Heart Failure. A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial // J. Am. Coll. Cardiol. — 2012. — Vol. 59. — Р. 585-92.
36. Talwalkar J.A., Lindor K.D. Primary biliary cirrhosis // Lancet. — 2003. — Vol. 362. — Р. 53-61.
37. Thomas C., Gioiello A., Noriega L. et al. TGR5-mediated bile acid sensing controls glucose homeostasis // Cell Metabolism. — 2009. — Vol. 10. — Р. 167-77.
38. Vassileva G., Hu W., Hoos L. et al. Gender–dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet–induced obese mice. Journal of Endocrinology. — 2010. — Vol. 205. — Р. 225-32.
39. Vassileva G., Golovko A., Markowitz L. et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochemical Journal. — 2006. — Vol. 398. — Р. 423-30.
40. Von Haehling S., Morley J.E., Anker S.D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. — 2010. — Vol. 1. — Р. 129-33.;
41. Von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. — 2010. — Vol. 1. — Р. 1-5.
42. Watanabe M., Houten S.M., Mataki C. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. — 2006. — Vol. 439. — Р. 484-9.
43. Wu T., Bound M.J., Standfield S.D. et al. Effects of rectal administration of taurocholic acid on glucagonlike peptide‑1 and peptide YY secretion in healthy humans. Diabetes, Obesity and Metabolism. — 2013. — Vol. 15. — Р. 474-7.
44. Yasuda H., Hirata S., Inoue K. et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells // Biochemical and Biophysical Research Communications. — 2007. — Vol. 354. — Р. 154-9.
2. Звенигородская Л.А., Мельникова Н.В. Гиполипидемическая терапия у больных с неалкогольной жировой болезнью печени: место гепатопротекторов // Гастроэнтерология. Приложение к журналу Consilium Medicum. — 2009. — № 1. — С. 32-6.
3. Abedin M.Z., Narins S.C., Park E.H. et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long–term study in prairie dogs // Dig. Dis. Sci. — 2002. — Vol. 47 (10). — Р. 2192-210.
4. Alemi F., Kwon E., Poole D.P. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia // Journal of Clinical Investigation. — 2013. — Vol. 123. — Р. 1513-30.
5. Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview // Heart. — 2004. — Vol. 90. — Р. 464-70.
6. Bernstein C., Holubec H., Bhattacharyya A.K. et al. Carcinogenicity of deoxycholate, a secondary bile acid // Archives of Toxicology. — 2011. — Vol. 85. — Р. 863-71.
7. Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hyperchole-sterolemia treatment: a prospective clinical trial (in Spanish) // Rev. Clin. Esp. — 2004. — Vol. 204 (12). — Р. 632-5.
8. Calmus Y., Guechot J., Podevin P. et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes // Hepatology. — 1992. — Vol. 16. — Р. 719-23.
9. Cao W., Tian W., Hong J. et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma // American Journal of Physiology — Gastrointestinal and Liver Physiology. — 2013. — Vol. 304. — Р. G322-G327.
10. Chen W. — D., Yu D., Forman B.M. et al. The deficiency of G-protein-coupled bile acid receptor gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis // Hepatology. — 2013. — Vol. 57 (2). — Р. 656-66.
11. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial // Circulation. — 2003. — Vol. 107. — Р. 3133-40.
12. Cipriani S., Mencarelli A., Chini M.G. et al. The bile acid receptor GPBAR‑1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis // PLoS ONE. — 2011. — Vol. 6. — Р. e25637.
13. Duboc H., Aelion H., Rainteau D. et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor? // Hepatology. — 2012. — Vol. 56. — Р. 24-6.
14. Evans K.A., Budzik B.W., Ross S.A. et al. Discovery of 3-aryl‑4-isoxazolecarboxamides as TGR5 receptor agonists // Journal of Medicinal Chemistry. — 2009. — Vol. 52. — Р. 7962-5.
15. Fiorucci S., Mencarelli A., Palladino G., Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders // Trends Pharmacol. Sci. — 2009. — Vol. 30. — Р. 570-80.
16. He G., Yu G. — Y., Temkin V. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stressdriven STAT3 activation // Cancer Cells. — 2010. — Vol. 17. — Р. 286-97.
17. Hong J., Behar J., Wands J. et al. Role of a novel bile acid receptor TGR5 in the development of osophageal adenocarcinoma // Gut. — 2010. — Vol. 59. — Р. 170-80.
18. Hov J.R., Keitel V., Laerdahl J.K. et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis // PLoS ONE. — 2010. — Vol. 5. — Р. e12403.
19. Ichikawa R., Takayama T., Yoneno K. et al. Bile acids induce monocyte differentiation toward interleukin‑12 hypo-producing dendritic cells via a TGR5-dependent pathway // Immunology. — 2012. — Vol. 136. — Р. 153-62.
20. Kawamata Y., Fujii R., Hosoya M. et al. A G protein-coupled receptor responsive to bile acids// Journal of Biological Chemistry. — 2003. — Vol. 278. — Р. 9435-40.
21. Keitel V., Donner M., Winandy S. et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells // Biochemical and Biophysical Research Communications. — 2008. — Vol. 372. — Р. 78-84.
22. Keitel V., Görg B., Bidmon H.J. et al. The bile acid receptor TGR5 (Gpbar‑1) acts as a neurosteroid receptor in brain // Glia. — 2010. — Vol. 58. — Р. 1794-805.
23. Keitel V., Reinehr R., Gatsios P. et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells // Hepatology. — 2007. — Vol. 45. — Р. 695-704.
24. Kida T., Tsubosaka Y., Hori M. et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells // Arteriosclerosis, Thrombosis, and Vascular Biology. — 2013. — Vol. 33. — Р. 1663-9.
25. Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) // Circulation. — 2004. — Vol. 109. — Р. 1594-602.
26. Maruyama T., Miyamoto Y., Nakamura T. et al. Identification of membrane-type receptor for bile acids (M-BAR) // Biochemical and Biophysical Research Communications. — 2002. — Vol. 298. — Р. 714-9.
27. Maruyama T., Tanaka K., Suzuki J. et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice // Journal of Endocrinology. — 2006. — Vol. 191. — Р. 197-205.
28. Marzioni M., Ueno Y., Glaser S. et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver // Liver International. — 2007. — Vol. 27. — Р. 558-68.
29. Müssig K., Staiger H., Machicao F. et al. Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus // Metabolism — Clinical and Experimental. — 2009. — Vol. 58. — Vol. 1809-11.
30. Pols T.W.H., Nomura M., Harach T. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading // Cell Metabolism. — 2011. — Vol. 14. — Р. 747-57.
31. Pols T.W.H., Noriega L.G., Nomura M. et al. The bile acid membrane receptor TGR5: a valuable metabolic target // Digestive Diseases. — 2011. — Vol. 29. — Р. 37-44.
32. Porez G., Prawitt J., Gross B., Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease // Journal of Lipid Research. — 2012. — Vol. 53. — Р. 1723-37.
33. Sandek A., Bauditz J., Swidsinski A. et al. Altered intestinal function in patients with chronic heart failure // J. Am. Coll. Cardiol. — 2007. — Vol. 50. — Р. 1561-69.
34. Sato H., Genet C., Strehle A. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea // Biochemical and Biophysical Research Communications. — 2007. — Vol. 362. — Р. 793-8.
35. von Haehling S., Schefold J.C., Jankowska E.A., Springer J., Vazir A., Kalra P.R., Sandek A., Fauler G., Stojakovic T., Trauner M., Ponikowski P., Volk H. — D., Doehner W., Coats A.J.S., Poole-Wilson P.A., Anker S.D. Ursodeoxycholic Acid in Patients With Chronic Heart Failure. A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial // J. Am. Coll. Cardiol. — 2012. — Vol. 59. — Р. 585-92.
36. Talwalkar J.A., Lindor K.D. Primary biliary cirrhosis // Lancet. — 2003. — Vol. 362. — Р. 53-61.
37. Thomas C., Gioiello A., Noriega L. et al. TGR5-mediated bile acid sensing controls glucose homeostasis // Cell Metabolism. — 2009. — Vol. 10. — Р. 167-77.
38. Vassileva G., Hu W., Hoos L. et al. Gender–dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet–induced obese mice. Journal of Endocrinology. — 2010. — Vol. 205. — Р. 225-32.
39. Vassileva G., Golovko A., Markowitz L. et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochemical Journal. — 2006. — Vol. 398. — Р. 423-30.
40. Von Haehling S., Morley J.E., Anker S.D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. — 2010. — Vol. 1. — Р. 129-33.;
41. Von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. — 2010. — Vol. 1. — Р. 1-5.
42. Watanabe M., Houten S.M., Mataki C. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. — 2006. — Vol. 439. — Р. 484-9.
43. Wu T., Bound M.J., Standfield S.D. et al. Effects of rectal administration of taurocholic acid on glucagonlike peptide‑1 and peptide YY secretion in healthy humans. Diabetes, Obesity and Metabolism. — 2013. — Vol. 15. — Р. 474-7.
44. Yasuda H., Hirata S., Inoue K. et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells // Biochemical and Biophysical Research Communications. — 2007. — Vol. 354. — Р. 154-9.
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Завантаження
Дані завантаження ще не доступні.